Nutritional correction of non-alcoholic fatty liver disease with the inclusion of a dietary supplement containing omega-3 PUFAs

Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent chronic liver pathologies worldwide, affecting more than a quarter of the global population. The disease is closely associated with obesity, insulin resistance, and metabolic syndrome. Although the Mediterranean diet has proven effective, adherence to it remains challenging, driving interest in combination therapy that includes dietary supplements. Omega-3 polyunsaturated fatty acids (EPA and DHA) are of particular importance, with a deficiency rate of 68.5 % in the Russian Federation and even lower levels observed in NAFLD patients.

Objective. To evaluate the efficacy of the dietary supplement «Triple Omega-3 950 mg» (ZAO “Evalar”) as part of nutritional correction in patients with NAFLD at the steatosis stage.

Materials and methods. An open-label comparative 6-month study enrolled 74 patients with NAFLD. The main group (n=50) received dietary therapy plus the supplement «Triple Omega-3 950 mg» (ZAO “Evalar”) (1 capsule/day: 950 mg omega-3 PUFAs, including not less than 550 mg EPA and not less than 230 mg DHA). The comparison group (n=24) received dietary therapy alone. Biochemical blood parameters, lipid profile, HOMA-IR index, liver enzymes, and abdominal ultrasound were assessed.

Results. The main group demonstrated a significant reduction in triglycerides (from 1.29±0.06 to 1.08±0.08 mmol/L) and LDL cholesterol (from 116.3±5.04 to 103.96±3.3 mg/mL) compared to the comparison group (p<0.05). Glucose levels decreased by 19.4 % (vs. 10.6 %), and the HOMAIR index decreased by 29.5 % (vs. 18 %). A marked reduction in ALT (by 76.3 %), AST (by 51.9 %), and GGT (by 57.9 %) activity was recorded. The supplement was well tolerated, with no adverse events reported.

Conclusion. The inclusion of the dietary supplement «Triple Omega-3 950 mg» (ZAO “Evalar”) in comprehensive dietary therapy for patients with NAFLD at the steatosis stage significantly improves lipid profile, reduces insulin resistance, alleviates cytolysis and cholestasis, and enhances patients’ quality of life. This product can be recommended as adjunctive therapy for NAFLD in combination with diet and physical activity.

1. Younossi Z.M., Golabi P., Paik J.M., Henry A., Dongen C. Van, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023; 77: 1335–1347. DOI: 10.1097/HEP.0000000000000004

2. Severson TJ, Besur S, Bonkovsky HL. Genetic factors that affect nonalcoholic fatty liver disease: a systematic clinical review. World J. Gastroenterol. 2016; 22: 6742–56. DOI: 10.3748/WJG.V22.I29.6742

3. Koyama Y, Brenner DA. Liver inflammation and fibrosis. J. Clin. Invest. 2017; 127: 55–64. DOI: 10.1172/JCI88881

4. Fernando DH, Forbes JM, Angus PW, Herath CB. Development and progression of non-alcoholic fatty liver disease: the role of advanced glycation end products. Int J. Mol. Sci. 2019; 20: 5037. DOI: 10.3390/IJMS20205037

5. Pierantonelli I, Svegliati-Baroni G. Nonalcoholic fatty liver disease: basic Pathogenetic mechanisms in the progression from NAFLD to NASH. Transplantation. 2019; 103: E1–E13. DOI: 10.1097/TP.0000000000002480

6. Utzschneider KM, Kahn SE. The role of insulin resistance in nonalcoholic fatty liver disease. J. Clin. Endocrinol. Metab. 2006; 91: 4753–61. DOI: 10.1210/JC.2006-0587

7. Kudaravalli P, John S. Nonalcoholic fatty liver. Tampa FL: StatPearls (2022); Mascaró CM, Bouzas C, Tur JA. Association between non-alcoholic fatty liver disease and Mediterranean lifestyle: a systematic review. Nutrients. 2022; 14: 49. DOI: 10.3390/NU14010049

8. Eshraghian A. Current and emerging pharmacological therapy for non-alcoholic fatty liver disease. World J. Gastroenterol. 2017; 23: 7495–504. DOI: 10.3748/WJG.V23.I42.7495

9. Makri ES, Makri E, Polyzos SA. Combination therapies for nonalcoholic fatty liver disease. J Pers Med. 2022; 12: 1166. DOI: 10.3390/JPM12071166

10. Maevskaya M.V., Kotovskaya Yu.V., Ivashkin V.T. et al. Consensus for physicians on the management of adult patients with non-alcoholic fatty liver disease and its main comorbid conditions. Therapeutic archive. 2022; 94 (2): 216–253.

11. Ivashkin V.T., Maevskaya M.V., Zharkova M.S. et al. Clinical guidelines of the Russian Society for the Study of the Liver, Russian Gastroenterological Association, Russian Association of Endocrinologists, Russian Association of Gerontologists and Geriatricians, and the National Society of Preventive Cardiology for the diagnosis and treatment of non-alcoholic fatty liver disease. Russian Journal of Gastroenterology, Hepatology, Proctology. 2022; 32 (4): 104–140.

12. Guo X., Yin X., Liu Z., Wang J. Non-alcoholic fatty liver disease (NAFLD) pathogenesis and natural products for prevention and treatment. Int. J. Mol. Sci. 2022; 23 (24): 15489

13. Musa-Veloso K., Venditti C., Lee H. Y. et al. Systematic review and meta-analysis of controlled intervention studies on the effectiveness of long-chain omega 3 fatty acids in patients with nonalcoholic fatty liver disease. Nutr. Rev. 2018; 76 (8): 581–602.

14. Kytikova O.Y., Novgorodtseva T.P., Antonyuk M.V., Denisenko Y.K., Gvozdenko Т.A. Pro-resolving lipid mediators in the pathophysiology of asthma. Medicine. 2019; 55 (6): 284. DOI: 10.3390/medicina55060284

15. Cicero AFG, Colletti A, Bellentani S. Nutraceutical approach to non-alcoholic fatty liver disease (NAFLD): the available clinical evidence. Nutrients. 2018; 10: 1153. DOI: 10.3390/NU10091153

16. Lu W, Li S, Li J, Wang J, Zhang R, Zhou Y. et al. Effects of Omega 3 fatty acid in nonalcoholic fatty liver disease: a meta-analysis. Gastroenterol. Res. Pract. 2016; 2016: 1–11. DOI: 10.1155/2016/1459790

17. Drapkina OM, Deeva TA, Volkova NP, Ivashkin VT. Current approaches to diagnosing and treating nonalcoholic fatty liver disease. Therapeutic Archive. 2014; 86 (10): 116–123. (In Russ.).

18. Kalinchenko S. Yu., Soloviev D.O., Avetisyan L.A. et al. Prevalence of Omega 3 Fatty Acid Deficiency in Different Age Groups. Dietetics Issues. 2018; 8 (1): 11–16.

19. Nobili V., Carpino G., Alisi A. et al. Role of docosahexaenoic acid treatment in improving liver histology in pediatric nonalcoholic fatty liver disease. PLoS ONE. 2014; 9: e88005.

20. Araya J., Rodrigo R., Videla L.A. et al. Increase in long-chain polyunsaturated fatty acid n 6/n 3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin. Sci. 2004; 106: 635–643.

21. James M.J., Gibson R.A., Cleland L.G. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am.J. Clin. Nutr. 2000; 71 (1): 343S 348S.